Associated Papers
Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC).
Garg PK et al.
Atherosclerosis, 2018
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Yeo A et al.
Plos One, 2017
Coronary heart disease and genetic variants with low phospholipase A2 activity.
Polfus LM et al.
The New England Journal of Medicine, 2015
Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene.
Stafforini DM
Pharmaceuticals (basel, Switzerland), 2009
Select a paper to view details